News

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

A look at the latest advances from flash photography to AI-driven OCT

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

Research was based on results of a double-blinded, randomized, clinical trial performed between November 2017 and December 2022 in the strabismus clinic of Farabi Eye Hospital.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.

According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, distinguished research scientist Fiona McDonnell, PhD, and Ian Pitha, MD, PhD, associate director of the Alan S. Crandall Center for Glaucoma Innovation

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.

According to presentations at FLORetina ICOOR 2024 in Florence, Italy, data show promising early improvements in low luminance visual acuity, a key measure of visual function. A pivotal Phase 2/3 VISTA trial for laru-zova in XLRP is currently enrolling.

With cases of syphilitic uveitis on the rise, recognizing its varied presentations—including optic disc edema, which may appear without other significant eye inflammation—is increasingly important for timely diagnosis and treatment.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

The use of ChatGPT may be premature to replace anterior segment experts.

A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD. At FLORetina ICOOR, he presented on a number of topics, including diabetic retinopathy—the subject of his conversation with the Eye Care Network.

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for dry eye disease.